Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2014-10-22 Share Issue/Capital Cha…
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Forendo Pharma closes EUR 12 million Series A financing round to develop a novel targeted therapy for endometriosis
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the successful closing of a EUR 12 million Series A financing round for Forendo Pharma. It details the investors involved (Novartis Venture Fund, MS Ventures, etc.) and the intended use of the proceeds (further development of a clinical candidate). This type of announcement, focusing on fundraising, capital structure changes, and the addition of new investors/board members, aligns best with the 'Capital/Financing Update' category. While it mentions new board members, the primary focus is the financing event itself. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a proxy statement (DEF 14A). Therefore, 'CAP' is the most appropriate classification.
2014-10-22 English
Earnings Release 2014
Earnings Release Classification · 1% confidence The document contains key elements typical of a periodic financial report, specifically mentioning 'Väsentliga händelser under tredje kvartalet' (Significant events during the third quarter) and presenting detailed financial tables comparing Q3 2014 results against previous periods (2013 Q3, 2014 YTD, 2013 YTD, 2013 Full Year). It includes a CEO commentary ('VD kommenterar') discussing strategy, portfolio changes, and key operational milestones (clinical trial updates, licensing deals). The structure, content (financial tables, management discussion, operational highlights for a specific period), and the focus on quarterly performance strongly indicate this is a comprehensive report for a period shorter than a year. This aligns perfectly with the definition of an Interim/Quarterly Report (IR). It is not an Earnings Release (ER) as it is comprehensive, nor is it an Annual Report (10-K). Since the document is extensive (140,008 characters) and contains the full details, it is classified as the report itself, not just a publication announcement (RPA). 9M 2014
2014-10-21 Swedish
Interim / Quarterly Report 2014
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Report' and covers the period of January to September 2014 (Q3). It contains comprehensive financial data, including a condensed income statement, balance sheet, and earnings per share, as well as detailed management commentary and strategic updates. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial analysis and data for a period shorter than a full fiscal year. 9M 2014
2014-10-21 English
Athera initiates Phase I trial with its fully human antibody PC-mAb
Regulatory Filings Classification · 1% confidence The document announces a specific corporate event: the initiation of a Phase I clinical trial for a product candidate (PC-mAb) by Athera Biotechnologies AB. It includes quotes from CEOs, details about the trial protocol, funding sources (EU FP7), and contact information. This type of announcement, detailing operational progress, clinical milestones, and strategic updates, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K or IR), a management discussion (MDA), or a transcript (CT), and it focuses on operational news rather than just dividends (DIV) or insider trades (DIRS), it fits best as an Earnings Release (ER) which often includes key operational highlights alongside financial context, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the structure announcing key progress, ER is the most appropriate fit among the specific operational/financial categories, as these operational updates often accompany or substitute for formal earnings releases in biotech/pharma sectors. However, since it is a specific operational/clinical update rather than a formal quarterly financial summary, and it doesn't explicitly state it's an 'Earnings Release', the general Regulatory Filing (RNS) category is a strong fallback for significant, non-standard corporate news. Given the context of a clinical trial initiation, which is a major operational milestone, and the lack of explicit financial reporting structure, I will classify it as a general Regulatory Filing (RNS) as it is a significant, non-standard announcement that doesn't fit the other specific operational/financial codes perfectly, although ER is plausible if this was released concurrently with quarterly results.
2014-10-21 English
Athera inleder fas I-studie med bolagets humana antikropp PC-mAb
Regulatory Filings Classification · 1% confidence The document is a press release dated October 21, 2014, announcing that Athera Biotechnologies has dosed the first healthy volunteers in a Phase I study for its human antibody PC-mAb, targeting cardiovascular diseases. This is a specific operational update regarding clinical trial progress and drug development milestones. It is not a comprehensive annual report (10-K), a quarterly report (IR), a formal earnings release (ER), or a transcript (CT). It is a specific announcement about a development stage, which fits best under general regulatory/corporate announcements. Since it details a significant operational event (start of a clinical trial) and is structured as a news release, it is most appropriately classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if it implied immediate funding needs, but the focus here is purely on the clinical trial initiation. Given the options, RNS serves as the best general category for specific, non-standard corporate news releases that don't fit the other specific financial/governance codes. The document length (4515 chars) is substantial enough to be the primary announcement, not just a notice of publication (RPA).
2014-10-21 Swedish
OssDsigns Cranioplug får marknadsgodkännande i USA
Regulatory Filings Classification · 1% confidence The document is a press release from OssDsign AB announcing that its product, Cranioplug, has received 510(k)-clearance from the US Food and Drug Administration (FDA). This is a specific announcement regarding regulatory approval for a medical device, which is a type of corporate event or material update. It is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a general regulatory filing (RNS). Since the definitions do not explicitly cover 'Regulatory Approval Announcement' for a product, the closest fit among the provided options that captures a significant, non-financial, non-management-change corporate update is 'Regulatory Filings' (RNS) as a general category, or potentially 'LTR' if it were related to legal proceedings, which it is not. Given the context of a specific, positive regulatory milestone announcement, RNS serves as the best general regulatory/corporate announcement fallback when a more specific category like 'Legal Proceedings Report' (LTR) is inappropriate. However, since this is a direct announcement of a regulatory milestone (FDA clearance), and it is not a standard financial report, RNS is the most appropriate catch-all for significant, non-standard corporate news.
2014-10-20 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.